Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11

Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11

BackgroundIrritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Probiotic-based strategies are increasingly being explored for IBS management, with growing interest in strain-specific app...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Bertuccioli, Davide Sisti, Nadia Lazzerini, Chiara Maria Palazzi, Giordano Bruno Zonzini, Mirko Ragazzini, Annalisa Belli
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Medicine
Subjects:
irritable bowel syndrome
Clostridium butyricum CBM588
Bifidobacterium longum W11
probiotics
IBS-D
IBS-C
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1604319/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items